Share this video  

ESMO 2019 | CheckMate 227 dual IO therapy: nivo plus ipilimumab upfront for NSCLC

Solange Peters • 28 Sep 2019
ESMO 2019
Lung Cancer Non-Small Cell Lung Cancer Checkpoint Inhibitors Ipilimumab Nivolumab
CheckMate 227 Immuno-Oncology

Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, presents the CheckMate 227 trial final analysis (NCT02477826) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Importantly, Prof. Peters highlights that nivolumab and low-dose ipilimumabwere well tolerated in non-small cell lung cancer. After the presentation, Marina Garassino, MD, National Cancer Institute of Milan, Milan, Italy, discusses the results and puts them in context.

More from Solange Peters

1:10
The BIRCH trial data discussed by Dr Peters
Solange Peters • 5 May 2017
2:22
ESMO 2016: From disease treatment to patient care
Solange Peters • 7 Oct 2016
0:50
Immunotherapy: will we reach a point where we can curatively treat advanced NSCLC?
Solange Peters • 24 Jan 2018
1:34
The role of immunotherapy in the radical treatment of NSCLC: where are we headed?
Solange Peters • 24 Jan 2018

Related Videos

1:49
Building a clinical research platform to capture and leverage data from cancer care in Germany
Frank Griesinger • 6 Dec 2016
2:12
ctDNA measurement via liquid biopsy: improving cancer detection and diagnosis
Pierre-Jean Lamy • 26 Nov 2018
0:45
How to discuss immunotherapy as a treatment option with lung cancer patients
Rolf Stahel • 29 Jan 2017
2:43
Clinical factors in the selection of patients for first-line immunotherapy of lung cancer
Benjamin Besse • 27 Jan 2017
The content of VJOncology is intended for healthcare professionals